EGFR and non-small cell lung carcinoma: However, the phase 3 RADIANTtrial [96] compared adjuvant erlotinib toplacebo in patients with completely resected, EGFR-positive Stage IB-IIIA NSCLC,found no significant improvement in DFS in the treatment arm versus placebo.However, a post hoc analysis of the patient subgroup withEGFR-activating mutations (EGFRm-positive), a small subset of the full studypopulation, found a trend toward better DFS with erlotinib (median DFS, 46 vs.29 months).